BridgeMD
An Early Phase Clinical Trial to Evaluate COM701 in Relapsed Platinum Sensitive Ovarian Cancer (PSOC)
EU CTIS ID: 2025-521125-33-00
What this study is testing
To evaluate the effect of COM701 as a single agent on Progression Free Survival when administered as a maintenance regimen in participants with relapsed PSOC.
- Phase I and Phase II (Integrated)- Other
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Has relapsed platinum sensitive epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer
- Has completed at least 2 previous courses (i.e. lines) of platinum-containing therapy
- Has received prior maintenance therapy with bevacizumab or a PARP inhibitor if eligible.
- Is able to provide written, informed consent before initiation of any study related procedures, and is able, in the opinion of the investigator, to comply with all the requirements of the study.
You likely can't join if
- Have any of the following histologies: clear cell carcinoma, low-grade serous carcinoma, malignant sex cord stromal tumors, malignant germ cell tumors, pure sarcoma
- Presence of radiographic or biopsy proven liver metastases at the beginning or completion of current line of platinum-based chemotherapy.
- Therapy with immunosuppressive doses of systemic medications, such as steroids (doses > 10 mg/day prednisone or equivalent daily) within 2 weeks before study drug administration.
- Prior PD-1, PD-L1, anti-PVRIG, TIGIT or any other check point inhibitors
- Have AEs from prior anti-cancer therapy that have not resolved to Grade ≤ 1, except alopecia of any grade and Grade 2 neuropathy.
- Have active hepatitis B virus (HBV) or hepatitis C virus (HCV), or participants with human immunodeficiency virus (HIV).
See the full eligibility criteria
- Has relapsed platinum sensitive epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer
- Has completed at least 2 previous courses (i.e. lines) of platinum-containing therapy
- Has received prior maintenance therapy with bevacizumab or a PARP inhibitor if eligible.
- Is able to provide written, informed consent before initiation of any study related procedures, and is able, in the opinion of the investigator, to comply with all the requirements of the study.
- Have any of the following histologies: clear cell carcinoma, low-grade serous carcinoma, malignant sex cord stromal tumors, malignant germ cell tumors, pure sarcoma
- Presence of radiographic or biopsy proven liver metastases at the beginning or completion of current line of platinum-based chemotherapy.
- Therapy with immunosuppressive doses of systemic medications, such as steroids (doses > 10 mg/day prednisone or equivalent daily) within 2 weeks before study drug administration.
- Prior PD-1, PD-L1, anti-PVRIG, TIGIT or any other check point inhibitors
- Have AEs from prior anti-cancer therapy that have not resolved to Grade ≤ 1, except alopecia of any grade and Grade 2 neuropathy.
- Have active hepatitis B virus (HBV) or hepatitis C virus (HCV), or participants with human immunodeficiency virus (HIV).
- Active and clinically relevant bacterial, fungal, or viral infection that is not controlled or requires systemic antibiotics, antifungals, or antivirals, respectively.
- Has had an allogeneic tissue/solid organ transplant.
- Received a live viral vaccine within 30 days of planned start of study treatment or requiring a live vaccine during the study.
- Females who are pregnant or breastfeeding or planning to become pregnant during the period of the study.
- History of severe allergic, anaphylactic, or other hypersensitivity reactions to a humanor humanized monoclonal antibody (mAb) or allergy to any excipients in theinvestigational products.
- Are currently participating in or have participated in a clinical study and received an investigational agent or used an investigational device within 4 weeks prior to the first dose of study treatment.
- Presence of any other condition that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the opinionof the investigator, would make the subject inappropriate for entry into the study.
- Participants residing in France deprived of their liberty by a judicial or administrative decision, and/or persons under psychiatric care within the meaning of Article L1121-6of the Public Health Code.
- Have 4 or more (inclusive of 4) lines of cytotoxic chemotherapy in total.
- Have a known additional malignancy that progressed or required active treatment within the last 5 years.
The study team makes the final eligibility decision.
Where it's taking place
- United States
- Israel
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United States; Israel. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.